Navigation Links
Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation's ONCONASE (ranpirnase) has shown potential to act as a potent payload in antibody conjugates for cancer therapy, according to the latest edition of the Handbook of Therapeutic Antibodies.

In a chapter of the text that reviews immunotoxins, Susanna Rybak, Ph.D. summarizes preclinical research indicating that the specificity and potency of ONCONASE improves in a number of tumor models, including non-Hodgkin's lymphoma, when it is conjugated with various antibodies. Dr. Rybak also reviews evidence that implies that ONCONASE may also be effectively targeted to tumors as a conjugate with non-internalizing antibodies, as compared with the internalizing antibodies required by standard plant and bacterial toxins.

"Antibody-targeted ONCONASE is the most potent targeted ribonuclease (RNase) that I have studied," Dr. Rybak said. "While immunotoxins have entered the arsenal of anti-cancer drugs, there have been problems with their clinical use. ONCONASE's excellent performance in preclinical studies makes it a very promising candidate for testing in the clinic."

"It is a great honor to be included in this important industry reference book," added Kuslima Shogen, Alfacell's chairman and chief executive officer. "This work is further evidence of the opportunity that exists for us to build a significant ONCONASE franchise, as a single agent, in combination therapy or as a payload in antibody conjugates. ONCONASE has the potential to be an effective, highly targeted agent for the treatment of various cancers beyond mesothelioma."

For more than 25 years, Dr. Rybak's research has centered on the biology of RNases, antibody engineering and drug targeting. Her laboratory at the National Cancer Institute (NCI) developed the groundwork for RNase-based therapeutics for NHL and breast cancer. Dr. Rybak, who is a member of Alfac ell's scientific advisory board, has been a long-term collaborator with the company.

The Handbook of Therapeutic Antibodies (ed: Stephen Dubel; published by Wiley VCH March 2007) presents an up-to-date and comprehensive review for the development, production and therapeutic application of antibodies. For more information, visit http://www.wiley.com.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are no t limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                    Investor Contact:

     David Schull or Wendy Lau         Andreas Marathovouniotis

     Noonan Russo                      Noonan Russo

     212-845-4271                      212-845-4253

              

     

david.schull@eurorscg.com andreas.marathis@eurorscg.com wendy.lau1@eurorscg.com

CONTACT: Media: David Schull, , or Wendy Lau,, +1-212-845-4271, or Investors: AndreasMarathovouniotis, +1-212-845-4253, , all ofNoonan Russo, for Alfacell Corporation david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com

Web site: http://www.alfacell.com/http://www.wiley.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media C ompany


'"/>




Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
9. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
10. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
11. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/5/2017)... MANCHESTER, England , July 5, 2017 ... the perfect answer as physics and manufacturing combine to progress ... the thyroid, existing SPECT systems are unable to accurately quantify ... consequence, only limited information regarding the success of this radiotherapy ... ...
(Date:6/30/2017)... -- In vitro diagnostics market firm Kalorama Information has ... ten diagnostic companies have successfully completed financings.  The types ... loan facility.  The size of these financings ranged from ... provides a monthly IVD Market Trends Report ... "Diagnostics deals are ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 2017 , ... Fresh Wave® IAQ today announced the launch of its innovative ... universities at the APPA 2017 Annual Conference and Exhibition in Booth #414. ... without the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric ...
(Date:7/21/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has written a ... and pleads with world leaders to be more open about positive changes. Yisrayl says the ... there is a peaceful and positive way to solve all; yes, all issues, and he ...
(Date:7/21/2017)... ... ... West Dermatology is pleased to announce the newest addition to their Fresno, ... will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing with ... more. She graduated from the University of Florida College of Medicine Physician Assistant Program ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
(Date:7/20/2017)... ... July 20, 2017 , ... Remote Medical ... their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ Telepathology ... participants for real-time collaboration and immediate decision-making requirements. While never sharing IP ...
Breaking Medicine News(10 mins):